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Introduction
The impact of cryopyrin associated periodic syndrome
(CAPS) on quality of life (QoL) is very high. Constitutional
symptoms, extreme fatigue, chronic pain and physical lim-
itation lead to severe restriction of daily activities and
social life. In addition neurological and sensory impair-
ments may aggravate social exclusion of these patients.
Objectives
To evaluate the quality of life, the social and professional
impact of a small cohort of CAPS patients after a long-
term treatment with Canakinumab, a selective anti inter-
leukine1b (IL-1b) monoclonal antibody.
Methods
Patients were those first included in the pivotal (D2304)
and in the extension (D2306) Canakinumab/CAPS study
[1] and followed in the reference center for autoinflamma-
tory diseases at Bicêtre Hospital (Paris). All carried a het-
erozygous mutation in the NLPR3 gene and had received
Canakinumab (dose of 150 mg every 8 weeks or 2mg/kg
for patient weight under 40kg). All patients had been
followed prospectively and their quality of life had been
evaluated regularly with generic questionnaires: Functional
Assessment of Chronic Illness Therapy-fatigue (FACIT-F),
36-item Short Form health survey (SF-36) and Health
Assessment Questionnaire (HAQ) for adults. Furthermore
supplementary questions regarding their social activities
and how they deal with their treatment were added.
Results
7 patients were analyzed (3males/4females, age 24 to
63-years-old). The mean time of follow-up from initial
treatment to last visit was 4.8 +/-0.8 years. All patients
were in remission defined as a physician global assessment
of disease activity that was minimal or absent, with skin
rash that was minimal or absent, and serum values of CRP
and/or SAA in the normal range. A significant and sus-
tained improvement in physical SF-36 (37.7 from baseline
vs 49,7 at end of D2306 study and 48.6 points at last visit,
p<0.05) and FACIT-F (25.1 vs 42,6 at end of D2306 study
and 42.3 points at last visit p<0.05) scores was found,
with scores approaching scores in American general
population. They notified modifications in their social
lives: 1 patient restarted professional activity, 4 patients
restarted with sportive activity and 1 patient stopped
smoking. Concerning their affective lives, 1 single man
patient lives actually in a relationship, and 1 patient
divorced. No local reaction after injection was observed
during the follow-up. Only 2 patients realized subcuta-
neous injections by their own, the 5 others needed a nurse
for the injection. Doses or intervals of injections were
modified in 4 patients because of incomplete remission
during follow-up (1 received 300 mg instead 150mg, and 3
received injections at 6 or 7 interval weeks).
Conclusion
Long-term treatment with Canakinumab in patients with
CAPS allows a sustained and significant improvement of
quality of life with the generic questionnaire FACIT-F and
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